CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2022

Mar 2, 2022

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name	of	Entity:	Chimeric Therapeutics Limited (ASX: CHM)
ACN:			638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	8 December 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [409 x 310] intentionally omitted <==

----- Start of picture text ----- Direct or Indirect Interest IndirectNature of indirect interest Director related entity(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.Date of change 1 March 2022No. of securities held prior to changeShares OptionsDirect 375,000 -Indirect 77,777,778 -Total 78,152,778 -Class Fully paid ordinary shares.Number acquiredShares OptionsDirect - -Indirect 2,941,176 -Total 2,941,176 -Number disposed Shares OptionsDirect - -Indirect - -Total - ------ End of picture text -----

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote:If consideration is non-cash, provide details and estimatedvaluation		$0.17 per share.
No. of securities held after change		SharesOptionsDirect375,000-Indirect80,718,954-Total81,093,954-
Nature of changeExample:on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back		Entitlement Offer.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [408 x 212] intentionally omitted <==

----- Start of picture text ----- Detail of contract N/ANature of interest N/AName of registered holder N/A(if issued securities)Date of change N/ANo. and class of securities to which N/Ainterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changedInterest acquired N/AInterest disposed N/AValue/Consideration N/ANote: If consideration is non-cash, provide detailsand an estimated valuationInterest after change N/A----- End of picture text -----

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or N/A contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [36 x 22] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3